Skip to content
lifestyle.floredechampagne.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NEUROCRINE BIOSCIENCES, INC.
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
October 12, 2026
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
September 30, 2026
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
September 2, 2026
Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
August 20, 2026
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-‘1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
August 19, 2026
Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
August 19, 2026
Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
June 3, 2026
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June
May 26, 2026
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
May 18, 2026
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
May 18, 2026
1
2
Next Page
→